5-fluorouracil-induced up-regulation of exosomal PD-L1 causing immunosuppression in gastric cancer patients

Min, Zhixue; Yibo, Fan; Xiaofang, C.; Hou, Kezuo; Qu, Xiujuan

doi:10.1093/annonc/mdy268.043

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this context, the addition of immunotherapy to chemotherapy regimens has the potential to serve to increase the sensitivity of tumors to immune checkpoint therapy and reduce the likelihood of tumor recurrence. Min et al (131) found that other cytotoxic drugs such as 5-FU and paclitaxel could increase PD-L1 expression. This shows that the combination of the two can serve to increase the efficacy.…”

Section: Combination With Chemotherapeutic Drugsmentioning

confidence: 99%

See 1 more Smart Citation

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges

Sun

Cheng

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

The occurrence and development of cancer are closely related to the immune escape of tumor cells and immune tolerance. Unlike previous surgical, chemotherapy, radiotherapy and targeted therapy, tumor immunotherapy is a therapeutic strategy that uses various means to stimulate and enhance the immune function of the body, and ultimately achieves the goal of controlling tumor cells.With the in-depth understanding of tumor immune escape mechanism and tumor microenvironment, and the in-depth study of tumor immunotherapy, immune checkpoint inhibitors represented by Programmed Death 1/Programmed cell Death-Ligand 1(PD-1/PD-L1) inhibitors are becoming increasingly significant in cancer medication treatment. employ a variety of ways to avoid detection by the immune system, a single strategy is not more effective in overcoming tumor immune evasion and metastasis. Combining different immune agents or other drugs can effectively address situations where immunotherapy is not efficacious, thereby increasing the chances of success and alternative access to alternative immunotherapy. Immune combination therapies for cancer have become a hot topic in cancer treatment today. In this paper, several combination therapeutic modalities of PD1/PD-L1 inhibitors are systematically reviewed. Finally, an analysis and outlook are provided in the context of the recent advances in combination therapy with PD1/PD-L1 inhibitors and the pressing issues in this field.

show abstract

Section: Combination With Chemotherapeutic Drugsmentioning

confidence: 99%

“…Min et al. ( 131 ) found that other cytotoxic drugs such as 5-FU and paclitaxel could increase PD-L1 expression. This shows that the combination of the two can serve to increase the efficacy.…”

Section: Combination With Chemotherapeutic Drugsmentioning

confidence: 99%

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges

Sun

Cheng

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…On the other hand, some reports are suggesting that other cytotoxic agents such as paclitaxel can increase the expression of PD-L1 [45]. At the same time, 5-FU, probably the most widely used chemotherapeutic agent in gastric and esophageal cancer, was demonstrated to increase the PD-L1 expression as well [46]. Considering these observations, using immunotherapy may be more appropriate with or after taxane/5-FU-based chemotherapy.…”

Section: Immune Checkpoints Pd-1/pd-l1/pd-l2 and Clinical Significmentioning

confidence: 99%

From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer

Vrána

Matzenauer

Neoral

et al. 2018

IJMS

113

View full text Add to dashboard Cite

Esophageal and gastric cancers represent tumors with poor prognosis. Unfortunately, radiotherapy, chemotherapy, and targeted therapy have made only limited progress in recent years in improving the generally disappointing outcome. Immunotherapy with checkpoint inhibitors is a novel treatment approach that quickly entered clinical practice in malignant melanoma and renal cell cancer, but the role in esophageal and gastric cancer is still poorly defined. The principal prognostic/predictive biomarkers for immunotherapy efficacy currently considered are PD-L1 expression along with defects in mismatch repair genes resulting in microsatellite instability (MSI-H) phenotype. The new molecular classification of gastric cancer also takes these factors into consideration. Available reports regarding PD-1, PD-L1, PD-L2 expression and MSI status in gastric and esophageal cancer are reviewed to summarize the clinical prognostic and predictive role together with potential clinical implications. The most important recently published clinical trials evaluating checkpoint inhibitor efficacy in these tumors are also summarized.

show abstract

“…[23] However, this might also depend on the chemotherapeutic regimen used -platinum compounds and anthracyclines reduce PD-L1 as compared to taxanes and antimetabolites that increase their levels. [24,25] Results of testing are also variable based on the nature of PD-L1 testing performed (pathological complete response vs. immunohistochemistry [IHC]) or the kind of reagents used (primers/antibodies). There is also lack of consensus on the cutoff value of PD-L1 positivity to be used for selecting patients (1% vs. 10% vs. 49% vs. 100%).…”

Section: How To Select Patients For Immunotherapymentioning

confidence: 99%

Immunotherapy in esophageal cancer – An update

Parekh¹,

Ghadlyalpatil

Chandarana³

et al. 2019

IJMIO

View full text Add to dashboard Cite

Esophageal cancer continues to remain a global problem. The majority of patients with advanced and/or metastatic disease will have limited survival, which has essentially remained unchanged over the past 20 years. The dawn of the immunotherapy resurgence has brought hope in the lives of many patients with lung cancer and other solid tumors. The emerging data for esophageal cancer also indicates benefit in selected patients. We summarize the current data available in this review.

show abstract

5-fluorouracil-induced up-regulation of exosomal PD-L1 causing immunosuppression in gastric cancer patients

Cited by 3 publications

References 0 publications

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges

From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer

Immunotherapy in esophageal cancer – An update

Contact Info

Product

Resources

About